Commodore Capital LP Has $12.57 Million Stock Position in Palisade Bio, Inc. $PALI

Commodore Capital LP reduced its stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) by 37.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,181,062 shares of the company’s stock after selling 4,263,938 shares during the quarter. Palisade Bio accounts for approximately 0.7% of Commodore Capital LP’s holdings, making the stock its 28th biggest position. Commodore Capital LP’s holdings in Palisade Bio were worth $12,567,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Total Clarity Wealth Management Inc. bought a new position in shares of Palisade Bio during the 4th quarter worth about $70,000. Jefferies Financial Group Inc. bought a new stake in shares of Palisade Bio in the fourth quarter valued at about $110,000. Geode Capital Management LLC lifted its stake in shares of Palisade Bio by 5,780.7% in the fourth quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock valued at $3,681,000 after buying an additional 1,538,832 shares during the period. Goldman Sachs Group Inc. acquired a new stake in Palisade Bio during the fourth quarter worth about $1,310,000. Finally, TD Asset Management Inc acquired a new stake in Palisade Bio during the fourth quarter worth about $480,000. 11.79% of the stock is owned by institutional investors.

Insider Transactions at Palisade Bio

In related news, insider Mitchell Lawrence Jones sold 51,880 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $2.05, for a total transaction of $106,354.00. Following the sale, the insider directly owned 94,009 shares in the company, valued at $192,718.45. This represents a 35.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John David Finley sold 146,798 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $2.07, for a total value of $303,871.86. Following the sale, the chief executive officer owned 217,555 shares in the company, valued at approximately $450,338.85. This trade represents a 40.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have acquired 125,000 shares of company stock valued at $250,100 in the last three months. 0.07% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have commented on the company. Oppenheimer began coverage on Palisade Bio in a report on Thursday. They issued an “outperform” rating and a $8.00 price target for the company. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday. Wolfe Research began coverage on Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price objective on the stock. LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Finally, Weiss Ratings lowered Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $9.00.

Palisade Bio Price Performance

Shares of PALI stock opened at $1.95 on Monday. The company has a market capitalization of $338.48 million, a P/E ratio of -1.93 and a beta of 1.50. Palisade Bio, Inc. has a 12-month low of $0.53 and a 12-month high of $2.86. The firm has a 50-day moving average price of $1.92 and a 200 day moving average price of $1.89.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, research analysts expect that Palisade Bio, Inc. will post -0.24 earnings per share for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.